Kimia biosciences Limited has filed its quarterly compliance certificate with BSE Limited, confirming adherence to SEBI regulations for the quarter ended March 31, 2026. The pharmaceutical company submitted the mandatory certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 on April 15, 2026.

Regulatory Compliance Submission

The compliance certificate was issued by Beetal Financial & Computer Services Private Limited, which serves as the company's Registrar and Share Transfer Agent (RTA). Company Secretary and Compliance Officer Abhishek K. Pandey submitted the documentation to BSE Limited, referencing the company's scrip code 530313.

RTA Confirmation Details

Beetal Financial & Computer Services Private Limited, a SEBI-approved Category I Registrar and Share Transfer Agent, provided comprehensive confirmation of compliance with dematerialization requirements. The RTA confirmed that securities received from Depository Participants during the quarter ended March 2026 were properly processed and confirmed to the depositories.

Compliance Verification

The certificate confirms several key compliance aspects:

• Securities received for dematerialization were accepted or rejected appropriately
• All securities have been listed on stock exchanges where previously issued securities are traded
• Security certificates received for dematerialization were mutilated and cancelled after verification
• Depository names were substituted in the register of members as registered owners within the mandated 15-day period

Corporate Structure

Kimia Biosciences Limited operates from its registered office and works at Village Bhondsi, Damdama Lake Road, Gurugram, Haryana. The company maintains its corporate office at Aggarwal Millennium Tower-II, Netaji Subhash Place, Pitampura, New Delhi. This regulatory filing demonstrates the company's commitment to maintaining compliance with SEBI depositories and participants regulations.

Kimia Biosciences Limited has issued a clarification to BSE Limited regarding significant price movement in its scrip, responding to an exchange inquiry dated April 13, 2026. The pharmaceutical company addressed concerns about unusual trading activity while reaffirming its commitment to regulatory compliance.

Regulatory Compliance Statement

The company confirmed its adherence to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30. Kimia Biosciences emphasized that it has been promptly informing the exchange of all events, information, and announcements that may impact its operations and performance.

Price Movement Clarification

The company categorically stated that there is no undisclosed price-sensitive information or pending announcements that could influence the scrip's price movement. Management clarified that the observed price fluctuations are purely market-driven and remain outside the company's control.

Corporate Governance Commitment

Kimia Biosciences reiterated its commitment to maintaining transparency with the stock exchange. The company assured continued compliance with applicable regulations and promised to keep the exchange informed of any material events as they develop.

The clarification was signed by Abhishek K. Pandey, Company Secretary & Compliance Officer, from the company's Delhi office. This response demonstrates the company's proactive approach to addressing regulatory inquiries and maintaining investor confidence through transparent communication.